Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Blood (2024) 144 (Supplement 1): 4080.

https://doi.org/10.1182/blood-2024-204647

Published: 2024

Journal Articles

Neutrophil PNH Type II Cells Are Associated with Thrombosis and Bone Marrow Failure without Hemolysis: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Orianne Wagner-Ballon, Anna Raimbault, Camille Debord, Valérie Soenen, Anne-Catherine Lhoumeau, Jean-Philippe Vial, Veronique Harrivel, Juliette Vo Xuan, Marie Loosveld, Gerard Socié, Regis Peffault De Latour, Ekbel Amri, Manuelle Rongy, Bernard Drenou, Agathe Debliquis, Magali Le Garff-Tavernier

Blood (2023) 142 (Supplement 1): 4083.

https://doi.org/10.1182/blood-2023-185645

Published: 2023

Journal Articles

Highly Sensitive Interleukin Score for Intra-Ocular Lymphoma Diagnosis: Evidence from Analysis of 5-Year Real-Life of Use

Blood (2023) 142 (Supplement 1): 3002.

https://doi.org/10.1182/blood-2023-182192

Published: 2023

Journal Articles

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Blood (2023) 142 (Supplement 1): 1516.

https://doi.org/10.1182/blood-2023-173379

Published: 2023

Journal Articles

Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Magali Le Garff-Tavernier, Jean-Philippe Vial, Thomas Boyer, Nicolas Chapuis, Véronique Harrivel, Anne-Catherine Lhoumeau, Elsa Bera, Isabelle Kittler, Marie Loosveld, Gerard Socie, Régis Peffault de Latour, Bernard Drenou, Agathe Debliquis, Orianne Wagner-Ballon

Blood (2022) 140 (Supplement 1): 8645–8647.

https://doi.org/10.1182/blood-2022-160207

Published: 2022

Journal Articles

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Blood (2022) 140 (Supplement 1): 6279–6281.

https://doi.org/10.1182/blood-2022-169696

Published: 2022

Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Blood (2022) 140 (Supplement 1): 7013–7015.

https://doi.org/10.1182/blood-2022-157963

Published: 2022

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

Efficacy of CAR-T Cells in Primary Central Nervous System Lymphomas: The French Experience of the National LOC Network

Blood (2022) 140 (Supplement 1): 7540–7541.

https://doi.org/10.1182/blood-2022-167784

Published: 2022

Journal Articles

CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network

Blood (2022) 139 (5): 792–796.

https://doi.org/10.1182/blood.2021012932

Published: 2022

Includes: Supplemental data

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blood (2021) 138 (Supplement 1): 641.

https://doi.org/10.1182/blood-2021-145624

Published: 2021

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features

Damien Roos-Weil, Brian Giacopelli, Marine Armand, Véronique Della-Valle, Hussein Ghamlouch, Camille Decaudin, Marlen Metzner, Junyan Lu, Magali Le Garff-Tavernier, Véronique Leblond, Paresh Vyas, Thorsten Zenz, Florence Nguyen-Khac, Olivier A. Bernard, Christopher C. Oakes

Blood (2020) 136 (5): 585–595.

https://doi.org/10.1182/blood.2020005081

Published: 2020

Includes: Supplemental data

Journal Articles

Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma

Blood (2020) 135 (20): 1811–1815.

https://doi.org/10.1182/blood.2019003073

Published: 2020

Journal Articles

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Blood (2019) 134 (21): 1821–1831.

https://doi.org/10.1182/blood.2019001187

Published: 2019

Includes: Supplemental data

Journal Articles

Persistence of PNH Clones over Time: Insights from the Mid-Term Analysis of the French Nation-Wide Multicenter Prospective Observational Study

Magali Le Garff-Tavernier, Agathe Pruvot Debliquis, PharmD, Thomas Boyer, MD, Jean-Philippe Vial, MD, Véronique Harrivel, MD, Anne-Catherine Lhoumeau, PhD PharmD, Marie-Christine Jacob, MD, Gerard Socie, MD PhD, Regis Peffault de Latour, MD PhD, Bernard Drenou, MD PhD, Orianne Wagner Ballon, MD PhD

Blood (2019) 134 (Supplement_1): 1218.

https://doi.org/10.1182/blood-2019-123415

Published: 2019

Journal Articles

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

Blood (2019) 134 (Supplement_1): 3038.

https://doi.org/10.1182/blood-2019-126720

Published: 2019

Journal Articles

p53 Functional Assessment and Correlation with 17p Deletion and/or TP53 Mutation Status: Final Report of the ICLL001 Bomp Trial

Blood (2018) 132 (Supplement 1): 3127.

https://doi.org/10.1182/blood-2018-99-116722

Published: 2018

Journal Articles

Genetic Characterization of B-Cell Prolymphocytic Leukemia (B-PLL): A Hierarchical Prognostic Model Involving MYC and TP53 Abnormalities. on Behalf of the Groupe Francophone De Cytogenetique Hematologique (GFCH) and the French Innovative Leukemia Organization (FILO) Group

Blood (2018) 132 (Supplement 1): 943.

https://doi.org/10.1182/blood-2018-99-115085

Published: 2018

Journal Articles

High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial

Blood (2018) 132 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2018-99-111977

Published: 2018

NARROW

High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone >1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Neutrophil PNH Type II Cells Are Associated with Thrombosis and Bone Marrow Failure without Hemolysis: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Highly Sensitive Interleukin Score for Intra-Ocular Lymphoma Diagnosis: Evidence from Analysis of 5-Year Real-Life of Use

Combination Chemotherapy in Patients with Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasms (BPDCN): First Results of a Prospective French Trial (LpDessai)

Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Efficacy of CAR-T Cells in Primary Central Nervous System Lymphomas: The French Experience of the National LOC Network

CAR T-cell therapy in primary central nervous system lymphoma: the clinical experience of the French LOC network

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features

Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Persistence of PNH Clones over Time: Insights from the Mid-Term Analysis of the French Nation-Wide Multicenter Prospective Observational Study

Maintenance of Long-Term Undetectable Minimal Residual Disease after Combination of Ibrutinib with Abbreviated Chemotherapy in the Icll-07 Filo Trial

p53 Functional Assessment and Correlation with 17p Deletion and/or TP53 Mutation Status: Final Report of the ICLL001 Bomp Trial

Genetic Characterization of B-Cell Prolymphocytic Leukemia (B-PLL): A Hierarchical Prognostic Model Involving MYC and TP53 Abnormalities. on Behalf of the Groupe Francophone De Cytogenetique Hematologique (GFCH) and the French Innovative Leukemia Organization (FILO) Group

High Rate of Complete Response (CR) with Undetectable Bone Marrow Minimal Residual Disease (MRD) after Chemo-Sparing and MRD-Driven Strategy for Untreated Fit CLL Patients: Final Results of the Icll 07 Filo Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only